CIBRA Capital Ltd Acquires New Holdings in Exact Sciences Corporation $EXAS

CIBRA Capital Ltd bought a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 39,400 shares of the medical research company’s stock, valued at approximately $4,001,000. Exact Sciences accounts for about 6.9% of CIBRA Capital Ltd’s holdings, making the stock its 8th biggest holding.

A number of other institutional investors have also made changes to their positions in the stock. Ameriprise Financial Inc. boosted its position in shares of Exact Sciences by 105.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock worth $245,802,000 after purchasing an additional 2,310,139 shares during the period. ARK Investment Management LLC raised its position in Exact Sciences by 6,072,588.9% in the third quarter. ARK Investment Management LLC now owns 2,186,168 shares of the medical research company’s stock valued at $119,605,000 after purchasing an additional 2,186,132 shares during the period. Holocene Advisors LP lifted its stake in Exact Sciences by 189.5% during the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock worth $113,995,000 after purchasing an additional 1,404,086 shares in the last quarter. Amova Asset Management Americas Inc. lifted its stake in Exact Sciences by 671.5% during the third quarter. Amova Asset Management Americas Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after purchasing an additional 1,119,830 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Exact Sciences by 643.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after buying an additional 1,113,459 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the topic of several research analyst reports. Zacks Research downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Evercore set a $105.00 price target on shares of Exact Sciences and gave the stock an “in-line” rating in a research note on Monday, January 5th. BTIG Research reissued a “neutral” rating on shares of Exact Sciences in a research note on Tuesday, March 24th. Finally, Mizuho restated a “neutral” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Exact Sciences has a consensus rating of “Reduce” and an average price target of $92.13.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $104.91 on Friday. The firm’s 50 day moving average price is $103.32 and its 200 day moving average price is $87.67. The stock has a market cap of $20.03 billion, a price-to-earnings ratio of -95.37, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $104.98. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The firm had revenue of $878.38 million for the quarter, compared to analyst estimates of $860.59 million. During the same quarter last year, the firm earned ($0.06) EPS. The company’s revenue was up 23.1% on a year-over-year basis. As a group, equities research analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.